The Innervation of Human Gut Sensory Epithelial Cells
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02888587|
Recruitment Status : Suspended (COVID-19 Restrictions)
First Posted : September 5, 2016
Last Update Posted : May 8, 2020
The study has two objectives:
- To obtain endoscopic and colonoscopic biopsies to harvest and culture intestinal crypts from human tissue to produce organoids. These organoids will be used to study the biology of innervated sensory epithelial cells.
- to collect subject data relating to clinical management and demographic characteristics of patients undergoing upper endoscopy or colonoscopy to learn the mechanisms behind visceral hypersensitivity, and neurodegenerative diseases that may arise in the gut.
|Condition or disease|
Throughout the gastrointestinal tract there are specialized sensory epithelial cells that recognize stimuli from nutrients and bacteria. These cells have been traditionally known for their endocrine function. However, it was recently discovered using mouse models that these cells receive synaptic inputs from enteric and peripheral neurons, such as those with cell bodies in dorsal root ganglia or the vagal nodose.
This finding opened a few possibilities, including the following: 1) sensory function of the gastrointestinal tract is modulated by neural activity; 2) gut bacteria influences brain function through a direct neural circuit; and 3) viruses that preferentially infect neurons access the central nervous system through this neural circuit [1,2]. To translate findings in animal models to humans, the investigator must test the hypotheses in which the physiology of gut sensory epithelial cells resembles that of humans.
Visceral hypersensitivity is a core symptom for several gastrointestinal and brain behavior disorders, including irritable bowel syndrome, autism and anorexia. Unfortunately, the basic mechanisms of sensory processing in the wall of the gut are non-existent. This lack of knowledge precludes the development of therapeutic strategies to treat disorders linked to visceral hypersensitivity. The investigator's efforts to translate animal research into human models will be a foundation to develop target therapies for visceral hypersensitivity.
Today, it is possible to derive organoids from intestinal crypts harvested from human intestinal or colonic tissue. The organoids have all epithelial cell types, including gut sensory cells. Here, the investigator's goal is to use de-identified human tissues to culture intestinal organoids in the laboratory, and use it as a platform to study the biology of innervated sensory epithelial cells. This work is significant because it will open the possibility to learn the mechanisms behind visceral sensation and neurodegenerative diseases that may arise in the gut.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||The Innervation of Human Gut Sensory Epithelial Cells|
|Actual Study Start Date :||September 5, 2017|
|Estimated Primary Completion Date :||October 2021|
|Estimated Study Completion Date :||October 2021|
no gastrointestinal symptoms
Patients with Visceral hypersensitivity
- Expression of sensory receptors in enteroendocrine cells [ Time Frame: 4 years ]Organoids are expected to contain enteroendocrine cells. We will use electrophysiology to measure the electrical excitability of these cells. In enteroendocrine cells from patients with a visceral hypersensitivity diagnosis is expected that cells will fire action potentials at a significantly lower threshold. These results will be correlated with RNA sequencing analysis to study the expression of sensory receptors in enteroendocrine cells.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02888587
|United States, North Carolina|
|Duke Medical Center|
|Durham, North Carolina, United States, 27710|